Top Tech Companies (2,065)
Don't see your company?
Create a company profile
Rare Disease Data Trust accelerates the discovery and diagnosis of targeted rare disease patients.
BioProcess Algae is a nutritionals and transportation pharmaceutical industries located in Omaha.
Tarsa Therapeutics develops an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.
Genomic Prediction provides advanced genomic tests which improve IVF health outcomes. Genomic Prediction Inc. (GP) was incorporated in Delaware, May 1, 2017. The research insights which led to the creation of GP stretch back much further. Research and data exchange agreements to develop molecular methodology, signed with some of the largest biotechnology vendors in the world, were ongoing as early as 2015. In the decade prior, the founders’ work in embryology, detection of chromosomal abnormality, computational genomics, algorithms, and polygenic architecture led to GP’s superior and innovative methodology for the genetic testing of human embryos. GP’s products incorporate fundamental improvements on existing methods. GP offers IVF parents a cost-effective means to evaluate genetic risk due to chromosomal abnormality (ploidy), single-gene mutations, and polygenic diseases. Accurate understanding of the genomic architecture of human disease requires larger training datasets, greater accuracy, and a more rigorous, empirical basis of computational modeling (machine learning) than implemented in the past with simpler technologies and simpler computational methods. GP represents the next step in embryo genetic testing, combining dense, genome-wide genotyping methods with sophisticated validation-focused modeling, suitable for the information age.
PolarityTE is revolutionary platform induces cell and tissue polarity, creating uniquely functional tissue.
Lynx Biosciences, Inc. is a cytomics company focused on transforming the development of blood cancer therapies.
Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA. The Company has assembled a toolkit of disruptive platform technologies – including a high payload capacity HSV platform, a hypoimmunogenic platform, and a genome writing platform – to address the scientific challenges currently limiting clinical progress and preventing genomic medicine from realising its full potential. The Company’s hub-and-spoke business model separates technology development within Replay from therapeutic development in product companies, which leverage the technology platforms. For example, Replay’s synHSV™ technology, a high payload capacity HSV vector capable of delivering up to 30 times the payload of AAV, is utilized by Replay’s four gene therapy product companies, bringing big DNA treatments to diseases affecting the skin, eye, brain, and muscle. The Company has, additionally, established an enzyme writing product company engaging its evolutionary inference machine learning and genome writing technology to optimize functionality. Replay is led by a world-class team of academics, entrepreneurs and industry experts.
Talis is developing a new class of diagnostic platform to enable rapid, high-complexity testing across a wide range of healthcare settings. Testing for COVID-19 is in high demand. Learn more about our product options. GenBody COVID-19 Ag Test Minimize disruptions with high-volume SARS-CoV-2 antigen testing and results in 15 minutes Learn more: https://talisbio.com/genbody-covid-19-antigen-test/ TALIS ONE™ COVID-19 TEST SYSTEM Rapid point-of-care COVID-19 test that enables highly sensitive SARS-CoV-2 RNA detection from nasal mid-turbinate swabs in less than 30 minutes. With its dual-gene target design, test sensitivity and inclusivity of variants are optimized. Learn more: https://talisbio.com/talis-one-covid-19-test-system/ Our visionary team combines depth of experience with passion to deliver a pioneering solution to infectious disease diagnostics. Infectious disease treatment today is largely guideline-driven: treat patients with similar symptoms the same. Unfortunately, similar symptoms can often have very different causes. Our tests will enable caregivers to know within minutes, the cause of illness, as well as which medications will be effective for their patient, empowering them to provide individualized care rather than broad, guideline-dictated treatments. From the doctor’s office to the hospital bedside to remote care settings, we are re-defining the treatment of infectious diseases.
CECO Environmental is a global leader in air quality and fluid handling serving the energy, industrial and other niche markets. Providing innovative technology and application expertise, CECO helps companies grow their business with safe, clean and more efficient solutions that help protect our shared environment. In regions around the world, CECO works to improve air quality, optimize the energy value chain and provide custom engineered solutions for applications including oil and gas, power generation, water and wastewater, battery production, poly silicon fabrication, chemical and petrochemical processing along with a range of others. CECO is listed on Nasdaq under the ticker symbol “CECE”. For more information, please visit www.cecoenviro.com.
AlphaCord is a stem cell banking company.
Poseida Therapeutics is a biotechnology company that utilizes genome engineering capabilities to develop targeted life-saving therapeutics.
Butler Technologies is an engineering and design-driven manufacturer specializing in printing, fabricating, and assembling custom products. While we have decades of experience with familiar products like graphic overlays and membrane switches, we are pushing the industry forward by prioritizing innovation through printed wearable technology like biometric sensors and flexible heaters. Our team of engineers and graphic artists offers the experience of a large national brand while maintaining the care and connection that comes with being a family-owned business.
Lapetus Solutions creates science and technology-based solutions for lifecycle event companies.
Demetrix is a biotechnology company that believes in the power of science to make the world a better place. The company produces effective health and wellness products backed by science, including rare, high-purity cannabinoids for pharmaceutical and consumer applications. Demetrix has a team of industry-leading experts across R&D, production, regulation, and commercialization, with deep experience bringing fermentation products to market. The company is pioneering the study of the more than 100 rare cannabinoids and their interactions with the human body.
CiiTA is provides expertise and actionable intelligence to pharmaceutical and biotechnology manufacturers.
AURA Devices is making smart wearables with bioimpedance technology as the fundamental one. We're helping athletes to achieve their goals and push their limits beyond.
BHS Biotechnology is a newly formed company, wholly owned by BioHybrid Solutions Holdings, Inc. (BHSH). All BHSH companies are endeavoring under the BioHybrid Solutions (BHS) banner. BHS’s vision is to deliver safe and effective biologic drugs to patients everywhere. Our mission is to harness science for the precise design and development of breakthrough biologic medicines. Our systematic in silico and in vitro process exerts ImmunoControl™ through our EpitopeSilencing™ process, improving pharmacokinetics and increasing the half-life of NanoArmored™ biologic therapeutics while maintaining activity. In addition, the ImmunoControlTM platform can be used for EpitopeTargeting™ and EpitopeAccentuation™ allowing for the discovery of new drugs against secondary, silent epitopes. Visit us at www.biohybridsolutions.com to learn more.
Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Biosplice’s target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular “command and control” center. Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer’s disease to other degenerative conditions. Learn more at https://www.biosplice.com
New reverse osmosis membranes are what the industry has been waiting for. Reverse osmosis has been proven to be the most efficient way to purify water. However, this process has also proven to be more expensive than what it could be. We will bring innovation to desalination by introducing these new membranes that will knock out biofouling and ultimately be more cost-efficient.
Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company that is driving the future of cellular immuno-oncology (IO).
